Piramal Pharma’s division -- Piramal Critical Care (PCC) has launched Chlorpromazine Hydrochloride for Injection, USP, which will be offered in 25mg/1mL and 50mg/2 mL vials. With this launch, PCC continues to expand their generic injectables portfolio.
The launch of Chlorpromazine Hydrochloride for Injection, USP (25mg/1mL and 50mg/2 mL vials) is the latest in a series of recent product launches from Piramal Critical Care in the generic injectables market. In 2024, PCC launched the first to market generic of Edaravone IV Infusion, which followed 2023 launches of Pantoprazole Sodium for Injection, USP and Doxycycline for Injection, USP to further enhance their wide portfolio of critical care products.
Piramal Pharma provides end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and global distribution network.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: